News

EC grants drug orphan status for AML, sarcoma


 

Micrograph showing AML

The European Commission (EC) has granted orphan drug designation to crenolanib for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma.

Crenolanib is a benzimidazole type I kinase inhibitor that selectively inhibits signaling of wild-type and mutant isoforms of FLT3 and PDGFRα/β.

The drug is under investigation as a treatment for multiple cancers. It is being developed by Arog Pharmaceuticals, Inc.

Results from a phase 2 trial of crenolanib in relapsed/refractory, FLT3+ AML were presented at the 2016 ASCO Annual Meeting.

About orphan designation

The EC grants orphan designation to therapies intended to treat life-threatening or chronically debilitating conditions affecting no more than 5 in 10,000 people in the European Union, and where no satisfactory treatment is available.

Orphan designation provides companies developing such drugs with regulatory and financial incentives, including protocol assistance, 10 years of market exclusivity once the drug is approved, and, in some cases, reductions in fees.

Recommended Reading

Targeted therapies predicted to blow out costs for CLL
MDedge Hematology and Oncology
Fourth approved indication for ofatumumab in chronic lymphocytic leukemia
MDedge Hematology and Oncology
Outcome of tumor lysis syndrome in pediatric patients with hematologic malignancies – a single-center experience from Pakistan
MDedge Hematology and Oncology
Acute-onset hypokalemic paralysis with arsenic trioxide therapy in patient with acute promyelocytic leukemia
MDedge Hematology and Oncology
Decitabine elicits favorable response in high-risk AML/MDS
MDedge Hematology and Oncology
Ph-like ALL is highly prevalent in adults
MDedge Hematology and Oncology
Idelalisib held unlikely to become frontline therapy for CLL
MDedge Hematology and Oncology
EC expands indication for arsenic trioxide in APL
MDedge Hematology and Oncology
Novel CLL drugs could greatly increase costs
MDedge Hematology and Oncology
ALL subtype ‘highly prevalent’ in adults
MDedge Hematology and Oncology